07:32 EDT MannKind (MNKD) to acquire scPharmaceuticals (SCPH) for up to $6.35 per share in cash
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind’s Growth Potential and Stability: Buy Rating Reinforced by Pipeline Progress and Strategic Catalysts
- MannKind Corporation’s Earnings Call Highlights Growth and Challenges
- MannKind Corporation Reports Q2 2025 Financial Growth
- Promising Outlook for MannKind: Buy Rating Justified by Clinical Progress and Financial Strength
- MannKind’s Strategic Growth Potential and Undervalued Stock: A Buy Rating Amid Market Overreactions